The development of improved treatments for neurological and psychiatric disorders is the greatest challenge confronting contemporary medicine. Indeed, neurodegenerative disorders, epitomized by Alzheimers, pose an ummatched threat to modern health care systems and the economic well being of society as a whole. Since 1995, NI Research has been the leading resource for independent information and analysis regarding the next generation of neurotherapeutics. It is to NI Research publications that the pharma industry and investment professionals turn for objective appraisals of scientific programs, companies seeking to bring them forward, and for consultation regarding strategy and licensing. NI Research emphasizes independence and objectivity: No advertising or sponsorships are accepted.
Harry Tracy PhD is the founder and President of NI Research. NIR’s quarterly publication, NeuroPerspective, is utilized by pharmaceutical companies and venture capital professionals around the world. NIR has also published NeuroLicensing and the Private CNS Company Review. NIR provides consulting services to pharmaceutical companies, ranging from the largest of major pharma companies to small startups, and to venture capital/private equity group assessing CNS investment opportunities.
Dr. Tracy’s background includes twenty-five years of experience as a clinician and consultant in a variety of psychiatric and neurological settings. He received his PhD from the University of Miami, and completed his clinical training at Massachusetts General Hospital/Harvard Medical School. He has been a Research Associate in the Dept. of Neurology at the University of California, Davis.
Harry M. Tracy PhD
NI Research Inc.
PO Box 1028 Cardiff, CA 92007